Atul Tantia files SEBI Reg 31(4) substantial acquisition disclosure for GPT Healthcare
Atul Tantia, via NSE filing dated 29 Jun 2026, submitted disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4). This regulation mandates disclosure when a person acquires shares or voting rights exceeding prescribed thresholds (typically 5%). The filing establishes that the acquirer has met disclosure obligations to the stock exchange and the public, a prerequisite for any subsequent open offer or negotiated transaction in a pharma company listed on NSE.
Why it mattersThe filing of Reg 31(4) confirms crossing of the 5% threshold under SEBI Takeover Regulations; the acquirer's identity and timing trigger board approval, public announcement, and potential open offer obligations-key gating items for any listed pharma M&A.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE CORPFACTS Archives · official
- Bar & Bench
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026